Ruggiero A. Bone and soft tissue sarcoma. Cancers (Basel). 2020;12(9). https://doi.org/10.3390/cancers12092609.
von Mehren M, Kane JM, Bui MM, Choy E, Connelly M, Dry S, et al. NCCN guidelines insights: soft tissue sarcoma, version 1.2021. J Natl Compr Cancer Netw. 2020;18(12):1604–12. https://doi.org/10.6004/jnccn.2020.0058.
Article
Google Scholar
Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options in Oncol. 2019;20(1):6. https://doi.org/10.1007/s11864-019-0606-9.
Article
Google Scholar
Yang Z, Zheng R, Zhang S, Zeng H, Li H, Chen W. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med. 2019;16(3):565–74. https://doi.org/10.20892/j.issn.2095-3941.2019.0041.
Article
PubMed
PubMed Central
Google Scholar
George S. Developments in systemic therapy for soft tissue and bone sarcomas. J Natl Compr Canc Netw. 2019;17(5.5):625–8. https://doi.org/10.6004/jnccn.2019.5020.
Article
CAS
PubMed
Google Scholar
Wilding CP, Elms ML, Judson I, Tan AC, Jones RL, Huang PH. The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Rev Anticancer Ther. 2019;19(11):971–91. https://doi.org/10.1080/14737140.2019.1686979.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bui NQ, Wang DS, Hiniker SM. Contemporary management of metastatic soft tissue sarcoma. Curr Probl Cancer. 2019;43(4):289–99. https://doi.org/10.1016/j.currproblcancer.2019.06.005.
Article
PubMed
Google Scholar
Kudlowitz D, Muggia F. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications. Expert Opin Drug Saf. 2014;13(6):681–5. https://doi.org/10.1517/14740338.2014.910193.
Article
PubMed
Google Scholar
Cecco S, Aliberti M, Baldo P, Giacomin E, Leone R. Safety and efficacy evaluation of albumin-bound paclitaxel. Expert Opin Drug Saf. 2014;13(4):511–20. https://doi.org/10.1517/14740338.2014.893293.
Article
CAS
PubMed
Google Scholar
Blair HA, Deeks ED. Albumin-bound paclitaxel: a review in non-small cell lung cancer. Drugs. 2015;75(17):2017–24. https://doi.org/10.1007/s40265-015-0484-9.
Article
CAS
PubMed
Google Scholar
Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang Z, et al. Encouraging pathological complete response rate from neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous carcinoma: preliminary outcome of a retrospective study. Cancer Manag Res. 2021;13:2163–70. https://doi.org/10.2147/CMAR.S298360.
Article
PubMed
PubMed Central
Google Scholar
Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, et al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol. 2021;16(9):1523–32. https://doi.org/10.1016/j.jtho.2021.03.027.
Article
CAS
PubMed
Google Scholar
Kim JS, Suh KJ, Lee DW, Woo GU, Kim M, Kim SH, et al. A real-world efficacy of nab-paclitaxel monotherapy in metastatic breast cancer. Cancer Res Treat. 2021. https://doi.org/10.4143/crt.2021.394.
Amoroso L, Castel V, Bisogno G, Casanova M, Marquez-Vega C, Chisholm JC, et al. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: a collaboration with the European Innovative Therapies for Children with Cancer Network. Eur J Cancer. 2020;135:89–97. https://doi.org/10.1016/j.ejca.2020.04.031.
Article
CAS
PubMed
Google Scholar
Oesterheld JE, Reed DR, Setty BA, Isakoff MS, Thompson P, Yin H, et al. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: a report from the National Pediatric Cancer Foundation. Pediatr Blood Cancer. 2020;67(7):e28370. https://doi.org/10.1002/pbc.28370.
Article
CAS
PubMed
PubMed Central
Google Scholar
Metts JL, Alazraki AL, Clark D, Amankwah EK, Wasilewski-Masker KJ, George BA, et al. Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas. Pediatr Blood Cancer. 2018;65(9):e27246. https://doi.org/10.1002/pbc.27246.
Article
CAS
PubMed
Google Scholar
Saerens M, Brusselaers N, Rottey S, Decruyenaere A, Creytens D, Lapeire L. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: a systematic review and meta-analysis. Eur J Cancer. 2021;152:165–82. https://doi.org/10.1016/j.ejca.2021.04.034.
Article
CAS
PubMed
Google Scholar
Rytlewski J, Milhem MM, Monga V. Turning ‘cold’ tumors ‘hot’: immunotherapies in sarcoma. Ann Transl Med. 2021;9(12):1039. https://doi.org/10.21037/atm-20-6041.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tawbi HA, Burgess M, Bolejack V, Tine BAV, Schuetze SM. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–501. https://doi.org/10.1016/S1470-2045(17)30624-1.
Article
CAS
PubMed
PubMed Central
Google Scholar
Salas-Benito D, Perez-Gracia JL, Ponz-Sarvise M, Rodriguez-Ruiz ME, Martinez-Forero I, Castanon E, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11(6):1353–67. https://doi.org/10.1158/2159-8290.CD-20-1312.
Article
CAS
PubMed
Google Scholar
Clemente O, Ottaiano A, Di Lorenzo G, Bracigliano A, Lamia S, Cannella L, et al. Is immunotherapy in the future of therapeutic management of sarcomas? J Transl Med. 2021;19(1):173. https://doi.org/10.1186/s12967-021-02829-y.
Article
CAS
PubMed
PubMed Central
Google Scholar
Livingston MB, Jagosky MH, Robinson MM, Ahrens WA, Benbow JH, Farhangfar CJ, et al. Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft tissue sarcoma. Clin Cancer Res. 2021. https://doi.org/10.1158/1078-0432.CCR-21-2001.
Shen D, Wang J, Wu J, Chen S, Li J, Liu J, et al. Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma. J Thorac Dis. 2021;13(3):1760–8. https://doi.org/10.21037/jtd-21-103.
Article
PubMed
PubMed Central
Google Scholar
Patel SA, Gerber DE, Deal A, Douglas K, Pecot CV, Lee C, et al. Consolidation with pembrolizumab and nab-paclitaxel after induction platinum-based chemotherapy for advanced non-small cell lung cancer. Front Oncol. 2021;11:666691. https://doi.org/10.3389/fonc.2021.666691.
Article
PubMed
PubMed Central
Google Scholar
Li JJ, Wang JH, Dingv Y, Li DD, Wen XZ, Zhao JJ, et al. Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. J Cancer Res Clin Oncol. 2021. https://doi.org/10.1007/s00432-021-03700-9.
Tian Z, Zhang F, Li P, Wang J, Yang J, Zhang P, et al. Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma. BMC Cancer. 2020;20(1):698. https://doi.org/10.1186/s12885-020-07199-0.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tian Z, Wang J, Yang J, Zhang P, Wang X, Zhang F, et al. Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study. Investig New Drugs. 2021. https://doi.org/10.1007/s10637-021-01139-w.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
Article
CAS
PubMed
Google Scholar
He M, Yang T, Wang Y, Wang M, Chen X, Ding D, et al. Immune checkpoint inhibitor-based strategies for synergistic cancer therapy. Adv Healthc Mater. 2021;10(9):e2002104. https://doi.org/10.1002/adhm.202002104.
Article
CAS
PubMed
Google Scholar
Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, et al. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1/2 nonrandomized clinical trial. JAMA Oncol. 2020;6(11):1778–82. https://doi.org/10.1001/jamaoncol.2020.3689.
Article
PubMed
Google Scholar
Chen Y, Liu R, Li C, Song Y, Liu G, Huang Q, et al. Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. Am J Cancer Res. 2021;11(7):3445–60.
CAS
PubMed
PubMed Central
Google Scholar
Zhang F, Huang D, Zhao L, Li T, Zhang S, Zhang G, et al. Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. Ther Adv Med Oncol. 2020;12:1758835920936882. https://doi.org/10.1177/1758835920936882.
Article
CAS
PubMed
PubMed Central
Google Scholar
Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(20):1397–410. https://doi.org/10.1016/S1470-2045(17)30622-8.
Article
CAS
PubMed
PubMed Central
Google Scholar